Bristol-Myers Squibb Selects Medidata Clinical Cloud® to Drive Drug Development and Business Transformation

NEW YORK–(BUSINESS WIRE)– Medidata
(NASDAQ:MDSO), the leading global provider of cloud-based solutions for
clinical research in life sciences, today announced that Bristol-Myers
Squibb (NYSE:BMY) has selected the Medidata
Clinical Cloud^® to help manage, monitor and analyze its
clinical trials. Medidata’s cutting-edge technology platform will
support Bristol-Myers Squibb’s research capabilities in immuno-oncology,
oncology, immunoscience, virology, cardiovascular, fibrotic diseases,
genetically modified diseases and metabolics.

The Medidata platform has been used by more than 630 customers around
the world – supporting more than 11,000 clinical studies, 420,000
investigational sites and more than 3.1 million trial volunteers –
driving a transformation in clinical trial design and execution, leading
to better science and new medical breakthroughs for patients.
Bristol-Myers Squibb will integrate Medidata’s data management, data
analytics and risk-based monitoring (RBM) capabilities into all stages
of its drug development process.

“Our agreement with Bristol-Myers Squibb is a great example of how the
world’s best clinical researchers are increasingly relying on Medidata
technology to help support advances in treatments for patients,” said
Medidata’s chief executive officer Tarek Sherif. “Medidata has developed
the most comprehensive cloud platform dedicated to clinical research,
powered by the world’s largest data repository. With our powerful and
flexible SaaS solution, we are helping our customers achieve meaningful
time-to-market results, as well as giving them the data and actionable
insights they need to innovate successfully.”

In adopting the Medidata Clinical Cloud platform across therapeutic
areas, Bristol-Myers Squibb will utilize a full suite of Medidata
solutions, including Medidata
Rave^® for electronic data capture, management and
reporting and Medidata’s RBM solutions, Medidata
TSDV and Medidata
CSA, enabling better prioritization of resources around key areas of
risk, such as patient safety and data quality and integrity.

A phased rollout is under way. Medidata has selected Accenture
(NYSE:ACN), a leading global professional services company providing a
broad range of services and solutions in strategy, consulting, digital,
technology and operations, to be its partner for specific elements of
the transformation project.

Connect with Medidata

• Read our blog, Geeks
  Talk Clinical
• Tweet this: Global
  #biopharma @BMSNews selects @Medidata #cloud platform to optimize
  #drugdev & drive business transformation http://ow.ly/4mUlta
• Follow us on Twitter: @Medidata
• Find us on LinkedIn

About Medidata

Medidata
is the leading global provider of cloud-based solutions for clinical
research in life sciences, transforming clinical development through its
advanced applications and intelligent data analytics. We are committed
to advancing the competitive and scientific goals of our life sciences
customers worldwide: more than 600 global pharmaceutical companies;
innovative biotech, diagnostic and device firms; leading academic
medical centers; and contract research organizations. Our
industry-leading technology platform, the Medidata Clinical Cloud^®,
is the primary technology solution powering clinical trials for 17 of
the world’s top 25 global pharmaceutical companies, bringing new levels
of productivity and quality to the clinical testing of promising medical
treatments, from study design and planning through execution, management
and reporting.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160420006471/en/